PolyPid Ltd. PYPD
Medical/Dental Instruments · IPO 2020 · data as of November 13, 2026
PolyPid Ltd. (PYPD) is a healthcare company listed in the US with a market value of about $127M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -137%.
About PolyPid
PolyPid is listed in the US and classified in medical/dental instruments, IPO year 2020. It was profitable in 1 of the last 8 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$34M | -$29M | -$24M | -$40M | -$43M | -$37M | -$7M | $6M |
| Free cash flow | -$28M | -$22M | -$17M | -$36M | -$35M | -$22M | -$18M | -$20M |
| EPS (diluted) | $-1.68 | $-1.43 | $-1.17 | $-1.95 | $-2.10 | $-1.82 | $-0.34 | $0.29 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -128.9% | -128.0% | -186.6% | -146.6% | -94.8% | -28.5% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $11.50, 84% above the current price; targets range from $8.50 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does PolyPid pay a dividend?
Not currently.
Is PolyPid a good stock to buy?
We do not give buy or sell advice. PolyPid scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.